SCHEMBL29067326

SCHEMBL29067326

O=CN1CCC(c2ccc(N3CCCC3)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRIM24 O15164 1/20 0.49
▸ TRIM33 Q9UPN9 1/20 0.49
▸ ALDH1A1 P00352 5/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ FAAH O00519 3/20 0.42
▸ PTGS2 P35354 2/20 0.41
▸ ACHE P22303 1/20 0.41
▸ PDE4B Q07343 1/20 0.41
▸ L3MBTL1 Q9Y468 3/20 0.41
▸ L3MBTL3 Q96JM7 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ TP53 P04637 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ ALOX15 P16050 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23064493 0.82 L3MBTL1 (0.52) TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3710421 0.78 SLC18A3 (0.52) ALDH1A1SMN1; SMN2TSHRMEN1KMT2A
SCHEMBL19971165 0.77 ATM (0.44) ALDH1A1NPC1RAB9A
SCHEMBL16994794 0.77 SLC18A3 (0.49) ALDH1A1SMN1; SMN2PDE4BNPC1TP53
SCHEMBL21285985 0.77 SLC18A3 (0.49) PDE4BEGFRLCKJAK3
SCHEMBL15364610 0.76 TRIM24 (0.61) TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E
SCHEMBL613794 0.76 ESR2 (0.55) TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E
SCHEMBL25318029 0.75 FAAH (0.52) ALDH1A1SMN1; SMN2KDM4EFAAHPTGS2
SCHEMBL4461599 0.75 HRH3 (0.50) TRIM24TRIM33ALDH1A1SMN1; SMN2KDM4E
SCHEMBL1673550 0.74 SIGMAR1 (0.52) ALDH1A1SMN1; SMN2KDM4EL3MBTL1L3MBTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043395-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING NEUROPORE THERAPIES, INC. 2024-02-08 — — US disclosed
EP-4217342-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING Neuropore Therapies, Inc. (US) 2023-08-02 — — EP disclosed
CN-116507607-A Compounds and compositions as modulators of TLR signaling 神经孔疗法股份有限公司 2023-07-28 — — CN disclosed
WO-2022067114-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING NEUROPORE THERAPIES, INC. (US) 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043395-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING TLR3, TLR6, TLR4 TRIM24 1262/4885TRIM33 2157/4885ALDH1A1 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback